Cargando…

Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking

This paper describes an ensemble method with supervised module detection and further module prioritization for reliable network-based biomarker discovery. We design a module detection and ranking method called mRank to discover reliable network modules as cancer diagnostic biomarkers, with two proce...

Descripción completa

Detalles Bibliográficos
Autores principales: Shang, Haixia, Liu, Zhi-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715301/
https://www.ncbi.nlm.nih.gov/pubmed/35024093
http://dx.doi.org/10.1016/j.csbj.2021.12.005
_version_ 1784624102256934912
author Shang, Haixia
Liu, Zhi-Ping
author_facet Shang, Haixia
Liu, Zhi-Ping
author_sort Shang, Haixia
collection PubMed
description This paper describes an ensemble method with supervised module detection and further module prioritization for reliable network-based biomarker discovery. We design a module detection and ranking method called mRank to discover reliable network modules as cancer diagnostic biomarkers, with two procedures: (1) an iterative supervised module detection guided by phenotypic states in a specific network, (2) a block-based module ranking locally and globally via network topological centrality. We validate its effectiveness and efficiency by identifying hepatocellular carcinoma (HCC) network modules on a comprehensive gene regulatory network with specifying gene interactions by HCC RNA-seq data from the Cancer Genome Atlas (TCGA). These top-ranked modules by mRank get a mean AUC of 0.995 on TCGA HCC dataset with 371 tumor samples and 50 controls by cross-validation SVM. Based on the prior knowledge of cancer dysfunctions enriched in top-ranked modules, 69 genes are identified as HCC candidate biomarkers. They are further validated in independent cohorts with a classifier trained on TCGA HCC dataset. A mean AUC of 0.846 is achieved in distinguishing 976 disease samples from 827 controls. Moreover, some known HCC signatures such as AFP and SPP1 are also included in our identified biomarkers. mRank enables us to find more reliable network modules for cancer diagnosis. For a proof-of-concept study, we validate it in identifying HCC network biomarkers and it is generalizable to other cancers or complex disease. The overall results have demonstrated that mRank can find effective network biomarkers for cancer diagnosis which result in less false positives.
format Online
Article
Text
id pubmed-8715301
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-87153012022-01-11 Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking Shang, Haixia Liu, Zhi-Ping Comput Struct Biotechnol J Research Article This paper describes an ensemble method with supervised module detection and further module prioritization for reliable network-based biomarker discovery. We design a module detection and ranking method called mRank to discover reliable network modules as cancer diagnostic biomarkers, with two procedures: (1) an iterative supervised module detection guided by phenotypic states in a specific network, (2) a block-based module ranking locally and globally via network topological centrality. We validate its effectiveness and efficiency by identifying hepatocellular carcinoma (HCC) network modules on a comprehensive gene regulatory network with specifying gene interactions by HCC RNA-seq data from the Cancer Genome Atlas (TCGA). These top-ranked modules by mRank get a mean AUC of 0.995 on TCGA HCC dataset with 371 tumor samples and 50 controls by cross-validation SVM. Based on the prior knowledge of cancer dysfunctions enriched in top-ranked modules, 69 genes are identified as HCC candidate biomarkers. They are further validated in independent cohorts with a classifier trained on TCGA HCC dataset. A mean AUC of 0.846 is achieved in distinguishing 976 disease samples from 827 controls. Moreover, some known HCC signatures such as AFP and SPP1 are also included in our identified biomarkers. mRank enables us to find more reliable network modules for cancer diagnosis. For a proof-of-concept study, we validate it in identifying HCC network biomarkers and it is generalizable to other cancers or complex disease. The overall results have demonstrated that mRank can find effective network biomarkers for cancer diagnosis which result in less false positives. Research Network of Computational and Structural Biotechnology 2021-12-08 /pmc/articles/PMC8715301/ /pubmed/35024093 http://dx.doi.org/10.1016/j.csbj.2021.12.005 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Shang, Haixia
Liu, Zhi-Ping
Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title_full Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title_fullStr Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title_full_unstemmed Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title_short Network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
title_sort network-based prioritization of cancer biomarkers by phenotype-driven module detection and ranking
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715301/
https://www.ncbi.nlm.nih.gov/pubmed/35024093
http://dx.doi.org/10.1016/j.csbj.2021.12.005
work_keys_str_mv AT shanghaixia networkbasedprioritizationofcancerbiomarkersbyphenotypedrivenmoduledetectionandranking
AT liuzhiping networkbasedprioritizationofcancerbiomarkersbyphenotypedrivenmoduledetectionandranking